Big pharma and private equity seek healthy returns in Europe s east Reuters 2 hrs ago © Reuters/DAVID W CERNY Trial run of the national vaccination centre in Prague
By Agnieszka Barteczko, Anna Koper and Michael Kahn
WARSAW/PRAGUE (Reuters) - In the race to supply vaccines to end the COVID-19 pandemic, U.S. drug developer Novavax turned to emerging Europe to speed up production with a pair of deals that endorsed a growing trend for consolidation in the region.
As part of a doubling in merger activity, buoyed by a combination of private equity and big pharma, Novavax bought the Praha Vaccines factory near Prague in a $167 million transaction last May. It followed up by partnering with Polish biotech company Mabion in March.
Big pharma and private equity seek healthy returns in Europe s east
reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
Big pharma and private equity seek healthy returns in Europe s east
reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
Big pharma and private equity seek healthy returns in Europe s east
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Big pharma and private equity seek healthy returns in Europe s east
netscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from netscape.com Daily Mail and Mail on Sunday newspapers.